Cookies

Like most websites The Translational Scientist uses cookies. In order to deliver a personalized, responsive service and to improve the site, we remember and store information about how you use it. Learn more.
Research Field Cancer, Immunology

Unlocking the Potential of Checkpoint Inhibition

 

At a Glance

International non-proprietary name (INN): Pembrolizumab
Brand name: Keytruda
Previous name: MK-3475, lambrolizumab
Developed by: Organon (acquired by Schering-Plough in 2007)
Marketed by: Merck & Co/MSD (merged with Schering-Plough in 2009)
Drug class: PD-1 inhibitor

Approval status: Approved in USA for advanced melanoma patients already treated with ipilimumab in September 2014 with an expanded indication granted in December 2015 for patients with unresectable or metastatic melanoma, and in October 2015 for treatment of patients with metastatic PD-L1-positive non-small cell lung cancer. In Europe, it has been recommended for the treatment of unresectable or metastatic melanoma since May 2015.

The Human Touch

David Matthews is associate director of biotherapeutics at MRC Technology. We spoke with Matthews to find out how MRC Technology helped the drug’s inventors take the first steps towards human trials.

Why is pembrolizumab important?

Firstly, it is active in hitherto very difficult-to-treat cancers, in some cases inducing complete remission, which is amazing. Secondly, it was the first successful PD-1 pathway inhibitor and one of the first checkpoint inhibitors. It’s a game-changing approach, and has opened our eyes to the possibility of targeting more cancers using similar mechanisms. The pharmaceutical industry is now putting a lot of investment and effort into understanding the pathways involved and hopefully coming up with more checkpoint inhibitors that can target more cancers.

Read the full article now

Log in or register to read this article in full and gain access to The Translational Scientist’s entire content archive. It’s FREE and always will be!

Login

Or register now - it’s free and always will be!

You will benefit from:

  • Unlimited access to ALL articles
  • News, interviews & opinions from leading industry experts
Register

Or Login via Social Media

By clicking on any of the above social media links, you are agreeing to our Privacy Notice.

About the Authors

Eric Rubin

Vice President of Oncology Clinical Research at Merck & Co.


David Matthews

Associate Director of Biotherapeutics at MRC Technology.

Related Solutions

Research Field Drug discovery

Dental Curing Lights: Clinical Reality

| Contributed by Ocean Optics

Research Field Genetics

Measuring DNA Absorbance with the STS-UV

| Contributed by Ocean Optics

Newsletter

Send me the latest from The Translational Scientist.

Sign up now

Register to The Translational Scientist

Register to access our FREE online portfolio, request the magazine in print and manage your preferences.

You will benefit from:

  • Unlimited access to ALL articles
  • News, interviews & opinions from leading industry experts

Register